Last A$0.09 AUD
Change Today +0.005 / 6.25%
Volume 286.6K
ACL On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 11:26 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd (ACL) Snapshot

Open
A$0.08
Previous Close
A$0.08
Day High
A$0.09
Day Low
A$0.08
52 Week High
09/11/14 - A$0.68
52 Week Low
11/13/14 - A$0.08
Market Cap
27.6M
Average Volume 10 Days
931.0K
EPS TTM
A$-0.02
Shares Outstanding
324.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALCHEMIA LTD (ACL)

Related News

No related news articles were found.

alchemia ltd (ACL) Related Businessweek News

No Related Businessweek News Found

alchemia ltd (ACL) Details

Alchemia Limited, a biotechnology company, develops human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies in Australia and the United States. Its technologies include HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. The company also provides generic fondaparinux, an anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, it develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer, as well as in the phase II investigator-sponsored trials that focuses on small cell lung cancer. The company has collaboration agreements with AstraZeneca AB to discover and develop novel small molecules against multiple targets; Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer; and IMBcom Asset Management Company for conducting research based upon certain voltage gated ion channel biological targets and library compounds, as well as with University of Queensland for ion channel drug discovery. Alchemia Limited also has research agreement with Monash University; and Cancer Research Technology Limited. The company was founded in 1995 and is headquartered in Brisbane, Australia.

29 Employees
Last Reported Date: 08/29/14
Founded in 1995

alchemia ltd (ACL) Top Compensated Officers

Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$235.7K
Vice President of Business Development
Total Annual Compensation: A$197.8K
Group Financial Controller
Total Annual Compensation: A$193.4K
Vice President of Drug Discovery
Total Annual Compensation: A$224.3K
Vice President of Intellectual Property & Tec...
Total Annual Compensation: A$223.9K
Compensation as of Fiscal Year 2014.

alchemia ltd (ACL) Key Developments

Alchemia Limited Announces Executive Changes

Alchemia Limited announced the departure of Thomas Liquard as Chief Executive Officer. In the interim, Dr. Tracie Ramsdale, current Non-Executive Director and former Chief Executive Officer of Alchemia, will be assuming an Executive Director role to help Alchemia during this transition.

Alchemia Limited - Shareholder/Analyst Call

To discuss the results of the Phase III trial

Alchemia Limited Proposes the Adoption of New Constitution

Alchemia Limited at its AGM to be held on November 11, 2014, will approve the ­adoption of new Constitution as that the existing Constitution of the company be repealed and the new constitution in the form tabled at the meeting (excluding rule 80), and signed by the Chair of the meeting for the purposes of identification, be adopted as the Constitution of the company, with effect from the close of the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACL:AU A$0.09 AUD +0.005

ACL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACL.
View Industry Companies
 

Industry Analysis

ACL

Industry Average

Valuation ACL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD, please visit www.alchemia.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.